Conditional Survival in de novo Metastatic Urothelial Carcinoma.
Second-line therapy is frequently utilized for metastatic urothelial carcinoma, but there are limited data to guide this approach. While an assessment of overall survival based on registry data may not capture the impact of second- and third-line therapies on clinical outcome, this may be reflected...
Main Authors: | Sumanta Kumar Pal, Yulan Ingrid Lin, Bertram Yuh, Kara DeWalt, Austin Kazarian, Nicholas Vogelzang, Rebecca A Nelson |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4550434?pdf=render |
Similar Items
-
Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
by: Sumanta K Pal, et al.
Published: (2013-01-01) -
Metastatic anal cloacogenic cell carcinoma misdiagnosed as urothelial carcinoma with long survival
by: Burak Bilgin, et al.
Published: (2017-07-01) -
CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer.
by: Sumanta K Pal, et al.
Published: (2014-01-01) -
Impact of modern chemotherapy on the survival of women presenting with <it>de novo</it> metastatic breast cancer
by: Pal Sumanta K, et al.
Published: (2012-09-01) -
Update on the Treatment of Metastatic Urothelial Carcinoma
by: Nedal Bukhari, et al.
Published: (2018-01-01)